BIOMARIN PHARMACEUTICAL INCBMRNEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 12.00% | 22.8M | ▲ +4.20pp | 2024-07-08 |
| The Vanguard Group | 10.00% | 19.0M | ▲ +0.42pp | 2024-07-10 |
| PRIMECAP Management Company | 9.78% | 18.4M | — | 2024-02-12 |
| S.S. OR | 7.40% | 14.0M | — | 2024-02-13 |
| OF ABOVE PERSONS | 5.70% | 10.8M | — | 2024-02-09 |
| Viking Global Investors LP | 5.10% | 9.8M | — | 2024-09-30 |
Insider Transactions
Net 90d: −$996.7K · buys $0 / sells $996.7KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-16 | Friberg Gregory R | EVP, Chief R&D Officer | Grant | 19.1K | $0.00 | $0 |
| 2026-03-16 | Cristin Hubbard | EVP, Chief Commercial Officer | Grant | 15.4K | $0.00 | $0 |
| 2026-03-16 | Brian Mueller | EVP, Chief Financial Officer | Grant | 18.7K | $0.00 | $0 |
| 2026-03-16 | Davis George Eric | EVP, Chief Legal Officer | Grant | 14.6K | $0.00 | $0 |
| 2026-03-16 | Guyer Charles Greg | EVP, Chief Technical Officer | Grant | 15.0K | $0.00 | $0 |
| 2026-03-16 | Alexander Hardy | Chief Executive Officer | Grant | 62.4K | $0.00 | $0 |
| 2026-03-11 | Guyer Charles Greg | EVP, Chief Technical Officer | Sell (open market) | 16.5K | $60.46 | $996.7K |
1–7 of 7